Search

Your search keyword '"Krop I"' showing total 299 results
Start Over Author "Krop I"
299 results on '"Krop I"'

3. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

Author

Curigliano, G., Mueller, V., Borges, V., Hamilton, E., Hurvitz, S., Loi, S., Murthy, R., Okines, A., Paplomata, E., Cameron, D., Carey, L.A., Gelmon, K., Hortobagyi, G.N., Krop, I., Loibl, S., Pegram, M., Slamon, D., Ramos, J., Feng, W., and Winer, E.

Published
2022
Full Text
View/download PDF

4. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker

Author

Mayer, E.L., Abramson, V., Jankowitz, R., Falkson, C., Marcom, P.K., Traina, T., Carey, L., Rimawi, M., Specht, J., Miller, K., Stearns, V., Tung, N., Perou, C., Richardson, A.L., Componeschi, K., Trippa, L., Tan-Wasielewski, Z., Timms, K., Krop, I., Wolff, A.C., and Winer, E.P.

Published
2020
Full Text
View/download PDF

6. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)

Author

Saura, C., primary, Modi, S., additional, Krop, I., additional, Park, Y.H., additional, Kim, S.-B., additional, Tamura, K., additional, Iwata, H., additional, Tsurutani, J., additional, Sohn, J., additional, Mathias, E., additional, Liu, Y., additional, Cathcart, J., additional, Singh, J., additional, and Yamashita, T., additional

Published
2023
Full Text
View/download PDF

8. Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis”

Author

Curigliano, G., primary, Mueller, V., additional, Borges, V., additional, Hamilton, E., additional, Hurvitz, S., additional, Loi, S., additional, Murthy, R., additional, Okines, A., additional, Paplomata, E., additional, Cameron, D., additional, Carey, L.A., additional, Gelmon, K., additional, Hortobagyi, G.N., additional, Krop, I., additional, Loibl, S., additional, Pegram, M., additional, Slamon, D., additional, Ramos, J., additional, Feng, W., additional, and Winer, E., additional

Published
2023
Full Text
View/download PDF

9. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)

Author

Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C.H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M.J., Carey, L., Corneliussen-James, D., Curigliano, G., Dieras, V., El Saghir, N., Eniu, A., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Gennari, A., Harbeck, N., Hudis, C., Kaufman, B., Krop, I., Mayer, M., Meijer, H., Mertz, S., Ohno, S., Pagani, O., Papadopoulos, E., Peccatori, F., Penault-Llorca, F., Piccart, M.J., Pierga, J.Y., Rugo, H., Shockney, L., Sledge, G., Swain, S., Thomssen, C., Tutt, A., Vorobiof, D., Xu, B., Norton, L., and Winer, E.

Published
2017
Full Text
View/download PDF

10. 186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2–positive (HER2+) metastatic breast cancer (mBC)

Author

Fehm, T.N., primary, Cottone, F., additional, Dunton, K., additional, André, F., additional, Krop, I., additional, Park, Y.H., additional, De Laurentiis, M., additional, Miyoshi, Y., additional, Armstrong, A., additional, Borrego, M. Ruiz, additional, Yerushalmi, R., additional, Duhoux, F.P., additional, Takano, T., additional, Lu, W., additional, Livings, C., additional, Egorov, A., additional, and Kim, S-B., additional

Published
2023
Full Text
View/download PDF

11. 6P Combined analysis of the HER2DX genomic tool in adjuvant APT and ATEMPT trials

Author

Tarantino, P., primary, Villacampa, G., additional, Graham, N., additional, Waks, A.G., additional, Gonzalez, P. Villagrasa, additional, Brasó-Maristany, F., additional, Torres, E. Sanfeliu, additional, Galván, P., additional, Brunet, L. Pare, additional, Demeo, M.K., additional, Partridge, A.H., additional, Burstein, H.J., additional, Krop, I., additional, Tayob, N., additional, Winer, E.P., additional, Prat, A., additional, and Tolaney, S.M., additional

Published
2023
Full Text
View/download PDF

12. 191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026)

Author

Hennessy, M.A., primary, Leal, J., additional, Huang, C-Y., additional, Solnes, L., additional, Denbow, R., additional, Abramson, V., additional, Carey, L., additional, Liu, M.C., additional, Rimawi, M., additional, Specht, J., additional, Storniolo, A.M.V., additional, Valero, V., additional, Vaklavas, C., additional, Winer, E., additional, Krop, I., additional, Wolff, A.C., additional, Cimino-Mathews, A., additional, Wahl, R., additional, Stearns, V., additional, and Connolly, R.M., additional

Published
2022
Full Text
View/download PDF

13. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Author

Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C.H., Bergh, J., Biganzoli, L., Blackwell, K.L., Cardoso, M.J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S.H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U.N., Mayer, M., Merjaver, S.D., Nordström, E.B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M.J., Rugo, H., Sledge, G., Thomssen, C., van’t Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., and Winer, E.

Published
2014
Full Text
View/download PDF

14. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Author

Cardoso, F, Costa, A, Senkus, E, Aapro, M, André, F, Barrios, C H, Bergh, J, Bhattacharyya, G, Biganzoli, L, Cardoso, M J, Carey, L, Corneliussen-James, D, Curigliano, G, Dieras, V, El Saghir, N, Eniu, A, Fallowfield, L, Fenech, D, Francis, P, Gelmon, K, Gennari, A, Harbeck, N, Hudis, C, Kaufman, B, Krop, I, Mayer, M, Meijer, H, Mertz, S, Ohno, S, Pagani, O, Papadopoulos, E, Peccatori, F, Penault-Llorca, F, Piccart, M J, Pierga, J Y, Rugo, H, Shockney, L, Sledge, G, Swain, S, Thomssen, C, Tutt, A, Vorobiof, D, Xu, B, Norton, L, and Winer, E

Published
2017
Full Text
View/download PDF

17. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

Author

Curigliano, G, Mueller, V, Borges, V, Hamilton, E, Hurvitz, S, Loi, S, Murthy, R, Okines, A, Paplomata, E, Cameron, D, Carey, LA, Gelmon, K, Hortobagyi, GN, Krop, I, Loibl, S, Pegram, M, Slamon, D, Ramos, J, Feng, W, Winer, E, Curigliano, G, Mueller, V, Borges, V, Hamilton, E, Hurvitz, S, Loi, S, Murthy, R, Okines, A, Paplomata, E, Cameron, D, Carey, LA, Gelmon, K, Hortobagyi, GN, Krop, I, Loibl, S, Pegram, M, Slamon, D, Ramos, J, Feng, W, and Winer, E

Abstract

BACKGROUND: In the primary analysis of the HER2CLIMB trial, tucatinib added to trastuzumab and capecitabine significantly improved overall survival (OS) and progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer. We report efficacy and safety outcomes, including the final OS and safety outcomes from follow-up in HER2CLIMB. PATIENTS AND METHODS: HER2CLIMB is a randomized, double-blind, placebo-controlled trial in patients with locally advanced or metastatic HER2+ breast cancer, including patients with brain metastases. Patients were randomized 2 : 1 to receive tucatinib or placebo, in combination with trastuzumab and capecitabine. After the primary analysis (median follow-up of 14 months), the protocol was amended to allow for unblinding sites to treatment assignment and cross-over from the placebo combination to the tucatinib combination. Protocol prespecified descriptive analyses of OS, PFS (by investigator assessment), and safety were carried out at ∼2 years from the last patient randomized. RESULTS: Six hundred and twelve patients enrolled in the HER2CLIMB trial. At a median OS follow-up of 29.6 months, median duration of OS was 24.7 months for the tucatinib combination group versus 19.2 months for the placebo combination group [hazard ratio (HR) for death: 0.73, 95% confidence interval (CI): 0.59-0.90, P = 0.004] and OS at 2 years was 51% and 40%, respectively. HRs for OS across prespecified subgroups were consistent with the HR for the overall study population. Median duration of PFS was 7.6 months for the tucatinib combination group versus 4.9 months for the placebo combination group (HR for progression or death: 0.57, 95% CI: 0.47-0.70, P < 0.00001) and PFS at 1 year was 29% and 14%, respectively. The tucatinib combination was well tolerated with a low rate of discontinuation due to adverse events. CONCLUSIONS: With additional follow-up, the tucatinib combination provided a clinicall

Published
2022

19. 1st International consensus guidelines for advanced breast cancer (ABC 1)

Author

Cardoso, F., Costa, A., Norton, L., Cameron, D., Cufer, T., Fallowfield, L., Francis, P., Gligorov, J., Kyriakides, S., Lin, N., Pagani, O., Senkus, E., Thomssen, C., Aapro, M., Bergh, J., Di Leo, A., El Saghir, N., Ganz, P.A., Gelmon, K., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Leadbeater, M., Mayer, M., Rodger, A., Rugo, H., Sacchini, V., Sledge, G., van’t Veer, L., Viale, G., Krop, I., and Winer, E.

Published
2012
Full Text
View/download PDF

20. 175P Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study

Author

Cardoso, F., primary, Juric, D., additional, Lerebours, F., additional, Krop, I., additional, Ruiz Borrego, M., additional, Neven, P., additional, Park, Y.H., additional, Yardley, D., additional, Jhaveri, K., additional, Arce, C., additional, Gu, E., additional, Akdere, M., additional, and Rugo, H.S., additional

Published
2022
Full Text
View/download PDF

21. Aktualisierte Ergebnisse von Tucatinib versus Placebo in Kombination mit Trastuzumab und Capecitabin bei Patienten mit vorbehandeltem, metastasierten HER2-positiven Brustkrebs mit ZNS-Metastasen (HER2CLIMB)

Author

Greil, R, additional, Lin, N U, additional, Murthy, R K, additional, Abramson, V, additional, Anders, C, additional, Bachelot, T, additional, Bedard, P L, additional, Borges, V, additional, Cameron, D, additional, Carey, L, additional, Chien, A J, additional, Curigliano, G, additional, DiGiovanna, M P, additional, Gelmon, K, additional, Hortobagyi, G, additional, Hurvitz, S, additional, Krop, I, additional, Loi, S, additional, Loibl, S, additional, Mueller, V, additional, Oliveira, M, additional, Paplomata, E, additional, Pegram, M, additional, Slamon, D, additional, Zelnak, A, additional, Ramos, J, additional, Feng, W, additional, and Winer, E., additional

Published
2022
Full Text
View/download PDF

22. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer

Author

Bellon, J.R., primary, Tayob, N., additional, Burstein, H.J., additional, Partridge, A., additional, Demeo, M.K., additional, Tralins, J., additional, Yang, D.D., additional, Dang, C., additional, Isakoff, S.J., additional, Yardley, D., additional, Valero, V., additional, Winer, E., additional, Krop, I., additional, and Tolaney, S., additional

Published
2021
Full Text
View/download PDF

24. 279P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)

Author

Saura Manich, C., primary, Modi, S., additional, Krop, I., additional, Park, Y.H., additional, Kim, S-B., additional, Tamura, K., additional, André, F., additional, Iwata, H., additional, Ito, Y., additional, Tsurutani, J., additional, Sohn, J., additional, Lee, C., additional, Liu, Y., additional, Cathcart, J., additional, Singh, J., additional, and Yamashita, T., additional

Published
2021
Full Text
View/download PDF

25. 120MO Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials

Author

Fernandez-Martinez, A., primary, Pascual, T., additional, Singh, B., additional, Nuciforo, P., additional, Hoadley, K.A., additional, Rashid, N.U., additional, Spears, P.A., additional, Chic, N., additional, Krop, I., additional, Hillman, D., additional, Partridge, A., additional, Prat, A., additional, Carey, L.A., additional, and Perou, C.M., additional

Published
2021
Full Text
View/download PDF

28. 377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03

Author

Hurvitz, S.A., Modi, S., Li, W., Park, Y.H., Chung, W., Kim, S-B., Cortés, J., Yamashita, T., Pedrini, J., Im, S-A., Tseng, L-M., Harbeck, N., Krop, I., Curigliano, G., Mathias, E., Cathcart, J., Cagnazzo, A., Ashfaque, S., Egorov, A., and André, F.

Published
2023
Full Text
View/download PDF

29. LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial

Author

Bardia, A., primary, Juric, D., additional, Shimizu, T., additional, Tolcher, A., additional, Karim, R., additional, Spira, A., additional, Mukohara, T., additional, Lisberg, A.E., additional, Kogawa, T., additional, Krop, I., additional, Papadopoulos, K.P., additional, Hamilton, E., additional, Damodaran, S., additional, Greenberg, J., additional, Gu, W., additional, Kobayashi, F., additional, Guevara, F., additional, Jikoh, T., additional, Kawasaki, Y., additional, and Meric-Bernstam, F., additional

Published
2021
Full Text
View/download PDF

34. Local���regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)

Author

Partridge, A.H., Ellis, M., Albain, K.S., Winer, E.P., Overmoyer, B.A., Carey, L.A., Rugo, H.S., Yardley, D.A., Krop, I., Wolff, A.C., Hudis, C.A., Guo, H., Moy, B., Marcom, P.K., Dang, C.T., Bellon, J.R., Burstein, H.J., Tolaney, S.M., and Barry, W.T.

Subjects
skin and connective tissue diseases
Abstract

Purpose: Women with HER2-positive breast cancer treated prior to effective anti-HER2 therapy have higher rates of local���regional recurrence (LRR) than those with HER2-negative disease. Effective systemic therapy, however, has been shown to decrease LRR. This study examines LRR in women with HER2-positive breast cancer treated on a single-arm prospective multicenter trial of adjuvant trastuzumab (H) and paclitaxel (T). Methods: Patients with HER2-positive tumors ��� 3.0 cm with negative axillary nodes or micrometastatic disease were eligible. Systemic therapy included weekly T and H for 12 weeks followed by continuation of H to complete 1 year. Radiation therapy (RT) was required following breast-conserving surgery (BCS), but dose and fields were not specified. Disease-free survival (DFS) and LRR-free survival were calculated using the Kaplan���Meier method. Results: Of the 410 patients enrolled from September 2007 to September 2010, 406 initiated protocol therapy and formed the basis of this analysis. A total of 272 (67%) had hormone receptor-positive tumors. Of 162 patients undergoing mastectomy, local therapy records were unavailable for two. None of the 160 for whom records were available received RT. Among 244 BCS patients, detailed RT records were available for 217 (89%). With a median follow-up of 6.5 years, 7-year DFS was 93.3% (95% CI 90.4���96.2), and LRR-free survival was 98.6% (95% CI 97.4���99.8). Conclusion: LRR in this select group of early-stage patients with HER2-positive disease receiving effective anti-HER2 therapy is extremely low. If confirmed in additional studies, future investigational efforts should focus on de-escalating local therapy.

Published
2019
Full Text
View/download PDF

41. Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Author

Metzger, O, primary, Mandrekar, S, additional, Loibl, S, additional, Mundhenke, C, additional, Seiler, S, additional, Valagussa, P, additional, Lim, E, additional, Tripathy, D, additional, Winer, EP, additional, Huang, C, additional, Carey, L, additional, Francis, P, additional, Miller, K, additional, Goetz, MP, additional, Prat, A, additional, Loi, S, additional, Krop, I, additional, Gianni, L, additional, Delalogue, S, additional, Vaz-Luis, I, additional, Dockter, T, additional, Lanzillotti, J, additional, Ciruelos, E, additional, and DeMichele, AM, additional

Published
2019
Full Text
View/download PDF

42. Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) using whole exome sequencing (WES)

Author

Cohen, O, primary, Buendia-Buendia, J, additional, Wander, S, additional, Nayar, U, additional, Mao, P, additional, Waks, A, additional, Kim, D, additional, Freeman, S, additional, Adalsteinsson, V, additional, Helvie, K, additional, Livitz, D, additional, Rosebrock, D, additional, Leshchiner, I, additional, Dellostritto, L, additional, Garrido-Castro, A, additional, Jain, E, additional, Periyasamy, S, additional, Mackichan, C, additional, Lloyd, M, additional, Marini, L, additional, Krop, I, additional, Garraway, L, additional, Getz, G, additional, Winer, E, additional, Lin, N, additional, and Wagle, N, additional

Published
2019
Full Text
View/download PDF

43. Abstract P1-15-01: Withdrawn

Author

Metzger Filho, O, primary, Janiszewska, M, additional, Guo, H, additional, Yardley, D, additional, Mayer, I, additional, Spring, L, additional, Arteaga, C, additional, Wrabel, E, additional, DeMeo, M, additional, Freedman, R, additional, Tolaney, S, additional, Waks, A, additional, Bardia, A, additional, Parsons, H, additional, Partridge, A, additional, Mayer, E, additional, King, T, additional, Polyak, K, additional, Viale, G, additional, Winer, E, additional, and Krop, I, additional

Published
2019
Full Text
View/download PDF

44. Corrigendum to '3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)' [Breast 31 (February 2017) 244-259]

Author

Cardoso, F., Costa, A., Senkus, E., Aapro, M., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M.J., Carey, L., Corneliussen-James, D, Curigliano, G, Dieras, V, El Saghir, N, Eniu, E, Fallowfield, L., Fenech, E, Francis, D, Gelmon, B, Gennari, D, Hudis, B, Kaufman, B., Krop, B, Meijer, D, Mertz, B, Ohno, B, Pagani, B, Papadopoulos, E., Peccatori, E, Penault-Llorca, L, Piccart, L, Pierga, D, Rugo, B, Shockney, L., Sledge, A, Swain, L, Thomssen, E, Tutt, L, Vorobiof, D., Xu, B., Norton, L., Winer, E., Eniu, A., Fenech, D., Francis, P., Gelmon, K., Gennari, A., Harbeck, N., Hudis, C., Krop, I., Mayer, M., Meijer, H., Mertz, S., Ohno, S., Pagani, O., Peccatori, F., Penault-Llorca, F., Piccart, M.J., Pierga, J.Y., Rugo, H., Sledge, G., Swain, S., Thomssen, C., Tutt, A., European School of Oncology & Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal, Champalimaud Clinical Center, European Institute of Oncology [Milan] (ESMO), Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland, Medical University of Gdansk, Breast Center, Genolier Cancer Center, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Department of Medicine, PUCRS School of Medicine, Department of Oncology–Pathology, Radiumhemmet, Karolinska University Hospital [Stockholm], Department of Medical Oncology, Fortis Hospital, 'Sandro Pitigliani' Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Breast Unit, Department of Hematology and Oncology, Lineberger Comprehensive Cancer Center (UNC Lineberger), University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC)-University of North Carolina System (UNC)-University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC)-University of North Carolina System (UNC), METAvivor Research and Support, MetaVivor Research and Support, Division of Experimental Therapeutics, Department of Medical Oncology, Institut Curie, Paris 75248, France, Brustzentrum der Universitat München, Universität München, Advanced BC.org, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Advanced breast, Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer, General Medicine, medicine.disease, 3. Good health, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, Surgery, business, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

46. Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients

Author

Specht, J., primary, Pusztai, L., additional, Forero-Torres, A., additional, Mita, M., additional, Weise, A., additional, Krop, I., additional, Grosse-Wilde, A., additional, Wang, Z., additional, Li, M., additional, Hengel, S., additional, Garfin, P., additional, Means, G., additional, Onsum, M., additional, and Modi, S., additional

Published
2018
Full Text
View/download PDF

47. OA02.07 Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or –Mutated Advanced Non-Small-Cell Lung Cancer

Author

Tsurutani, J., primary, Park, H., additional, Doi, T., additional, Modi, S., additional, Takahashi, S., additional, Nakagawa, K., additional, Krop, I., additional, Waqar, S., additional, Yoh, K., additional, Li, B., additional, Taira, S., additional, Jikoh, T., additional, Singh, J., additional, Sugihara, M., additional, and Jänne, P., additional

Published
2018
Full Text
View/download PDF

48. PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Author

Loibl, S., primary, Metzger, O., additional, Mandrekar, S.J., additional, Mundhenke, C., additional, Seiler, S., additional, Valagussa, P., additional, DeMichele, A., additional, Lim, E., additional, Tripathy, D., additional, Winer, E.P., additional, Huang, C., additional, Carey, L., additional, Francis, P., additional, Miller, K.D., additional, Goetz, M.P., additional, Prat, A., additional, Loi, S., additional, Krop, I., additional, Gianni, L., additional, and Ciruelos, E.M., additional

Published
2018
Full Text
View/download PDF

49. Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer

Author

Prat, A, primary, De Angelis, C, additional, Pascual, T, additional, Gutierrez, C, additional, Wang, T, additional, Paré, L, additional, Rexer, B, additional, Cortes, J, additional, Forero, A, additional, Llombart, A, additional, Wolff, AC, additional, Krop, I, additional, Galván, P, additional, Pavlick, AC, additional, Villagrasa, P, additional, Hilsenbeck, SG, additional, Schiff, R, additional, Osborne, CK, additional, and Rimawi, MF, additional

Published
2018
Full Text
View/download PDF

50. Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer

Author

Modi, S, primary, Pusztai, L, additional, Forero, A, additional, Mita, M, additional, Miller, KD, additional, Weise, A, additional, Krop, I, additional, Burris, H, additional, Kalinsky, K, additional, Tsai, M, additional, Liu, MC, additional, Hurvitz, SA, additional, Wilks, S, additional, Ademuyiwa, F, additional, Diab, S, additional, Han, HS, additional, Kato, G, additional, Nanda, R, additional, O'Shaughnessy, J, additional, Kostic, A, additional, Li, M, additional, and Specht, J, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results